Literature DB >> 23967752

Prevalence of asthma and severity of allergic rhinitis comparing 2 perennial allergens: house dust mites and Parietaria judaica pollen.

A Sala-Cunill1, J Bartra, G Dalmau, R Tella, E Botey, E Raga, A Valero.   

Abstract

BACKGROUND: Allergic rhinitis (AR) is an increasingly prevalent worldwide disease that has a considerable impact on quality of life and health care costs. Asthma and AR may be part of the same disease, with AR leading to an increased risk of asthma.
OBJECTIVES: To assess the prevalence of asthma in patients with AR due to house dust mites (HDMs) or Parietaria judaica and analyze the characteristics of asthma and AR in each group.
METHODS: Cross-sectional, multicenter study with recording of demographic and clinical characteristics. All patients had AR confirmed by symptoms and a positive skin prick test to HDMs or P judaica. They were classified according to the severity and frequency ofAR following the Allergic Rhinitis and its Impact on Asthma (ARIA) and modified ARIA criteria and according to the severity of asthma following the Global Initiative for Asthma criteria.
RESULTS: We studied 395 patients (226 in the HDM group and 169 in the Pjudaica group) with a mean (SD) age of 43 (15.3) years. Using the modified ARIA criteria, we detected more severe and persistent AR in the P judaica group than in the HDM group (44.5% vs 24.8%, P < .001). Nevertheless, there were no statistically significant differences between the groups in terms of the severity or prevalence (50% in HDM vs 47.9% in P judaica, P = .685) of asthma.
CONCLUSION: AR due to P judaica pollen, which behaves like a perennial allergen, is associated with the same prevalence of asthma and with more severe rhinitis than AR due to HDMs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23967752

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  6 in total

Review 1.  Subcutaneous immunotherapy with depigmented-polymerized allergen extracts: a systematic review and meta-analysis.

Authors:  Ralph Mösges; Antonio Valero Santiago; Silke Allekotte; Nilufar Jahed; Anatoli Astvatsatourov; Angelika Sager; Jaime Sánchez-López
Journal:  Clin Transl Allergy       Date:  2019-06-05       Impact factor: 5.871

2.  In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial.

Authors:  Corina I Bocşan; Adriana I Bujor; Nicolae Miron; Ştefan C Vesa; Diana Deleanu; Anca D Buzoianu
Journal:  Balkan Med J       Date:  2015-10-01       Impact factor: 2.021

Review 3.  Allergens with Protease Activity from House Dust Mites.

Authors:  Manuel Reithofer; Beatrice Jahn-Schmid
Journal:  Int J Mol Sci       Date:  2017-06-27       Impact factor: 5.923

4.  Allergic rhinitis: Disease characteristics and coping measures in Saudi Arabia.

Authors:  Abdulmohsin A Almehizia; Reema K AlEssa; Khalid M Alwusaidi; Khalid A Alzamil; Modhi AlJumah; Sarah Aljohani; Adel F Almutairi; Mahmoud Salam
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

5.  Expression and characterization of recombinant Par j 1 and Par j 2 resembling the allergenic epitopes of Parietaria judaica pollen.

Authors:  Yulia Dorofeeva; Paolo Colombo; Miguel Blanca; Adriano Mari; Roman Khanferyan; Rudolf Valenta; Margarete Focke-Tejkl
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

6.  Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap.

Authors:  Luisa Ricciardi; Francesco Papia; Marta Liotta; Francesca Cicero; Stefania Isola; Gennaro Tartarisco; Fabiana Furci; Sebastiano Gangemi
Journal:  Postepy Dermatol Alergol       Date:  2022-02-28       Impact factor: 1.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.